How many Efgartigimod PH20 SC clinical trials are there?

66 Efgartigimod PH20 SC clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 22 are actively recruiting participants. 18 are marked completed.

Are Efgartigimod PH20 SC clinical trials recruiting in 2026?

Yes — 22 Efgartigimod PH20 SC trials are actively recruiting in 2026, with 110 U.S. sites across 34 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Efgartigimod PH20 SC being studied for?

Efgartigimod PH20 SC is being studied for Generalized Myasthenia Gravis, Myasthenia Gravis, gMG, Primary Immune Thrombocytopenia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and 66 more. The trials are grouped by indication on this page.

What phase is Efgartigimod PH20 SC in?

Efgartigimod PH20 SC clinical trials span 5 Phase 4, 24 Phase 3, 19 Phase 2, 4 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Efgartigimod PH20 SC clinical trials?

The lead sponsor across the most Efgartigimod PH20 SC trials is argenx, with 17 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Efgartigimod PH20 SC Clinical Trials (2026): 66 Studies for Generalized Myasthenia Gravis & Myasthenia Gravis

Creator: Hipa.ai Research
Published: 2026-06-02T16:58:16.299Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 12, 2026.

66 Efgartigimod PH20 SC clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 41 indications (including Generalized Myasthenia Gravis & Myasthenia Gravis) and 6,711 total planned enrollment. 24 Phase 3 Efgartigimod PH20 SC trials and 19 Phase 2, 5 Phase 4 are listed. 33 Efgartigimod PH20 SC clinical trials are actively recruiting at 110 U.S. sites across 34 states. Most recent activity: NCT06298565 (Jun 2034).

Where to Participate: All Efgartigimod PH20 SC Trial Sites in the U.S. (110 sites across 34 states)

Every actively recruiting Efgartigimod PH20 SCtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	University of Alabama at Birmingham (UAB) Hospital	Birmingham35233	NCT06503731	Map
AZ	Arizona Arthritis and Rheumatology Associates	Phoenix85032-9306	NCT06655155	Map
AZ	Mayo Clinic Hospital Scottsdale	Phoenix85054	NCT06544499	Map
CA	Profound Research LLC - Carlsbad	Carlsbad92011	NCT07284420	Map
CA	Profound Research LLC - Carlsbad	Carlsbad92011	NCT07294170	Map
CA	Neurology Center of North Orange County	Fullerton92835	NCT07217587	Map
CA	University of California, San Diego - Altman Clinical and Translational Research Institute (ACTRI)	La Jolla92037	NCT06909214	Map
CA	Cedars-Sinai Medical Center	Los Angeles90048	NCT06503731	Map
CA	UCLA Ronald Reagan University of California Los Angeles Medical Center	Los Angeles90095	NCT06655155	Map
CA	University of Southern California Norris Comprehensive Cancer Center	Los Angeles90033	NCT06544499	Map
CA	Sharp Memorial Hospital	Oceanside92056	NCT06544499	Map
CA	Stanford University	Palo Alto94304-2210	NCT07025330	Map
CA	The Neurology Group	Pomona91767	NCT07217587	Map
CA	Samir Macwan, M.D., Inc. (S corporation)	Rancho Mirage92270	NCT06909214	Map
CA	UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center - Brain Tumor Center,	San Francisco94143	NCT06298565	Map
CO	University of Colorado	Aurora80045	NCT06860633	Map
CO	University of Colorado Hospital	Aurora80045	NCT06544499	Map
CO	Advanced Neurology of Colorado	Fort Collins80528	NCT07217587	Map
CT	University of Connecticut	Farmington06030	NCT07217587	Map
CT	Yale University School of Medicine	New Haven06510	NCT06544499	Map
DC	Georgetown University Hospital	Washington D.C.20007	NCT06544499	Map
FL	EZR Research	Boca Raton33486	NCT06909214	Map
FL	SFM Clinical Research LLC	Boca Raton33487	NCT07217587	Map
FL	SFM Clinical Research, LLC	Boca Raton33487	NCT06298565	Map
FL	University of Florida Jacksonville	Jacksonville32209	NCT06909214	Map
FL	University of Florida College of Medicine Jacksonville	Jacksonville Beach32209	NCT06298565	Map
FL	Visionary Investigators Network	Miami33133	NCT06909214	Map
FL	Visionary Investigators Network	Miami33176	NCT07284420	Map
FL	Visionary Investigators Network	Miami33133	NCT07294170	Map
FL	University of California Irvine	Orange92868	NCT06909214	Map
FL	IRIS Research and Development LLC	Plantation33324	NCT06655155	Map
FL	Medsol Clinical Research Center Inc	Port Charlotte33952	NCT06298565	Map
FL	Medsol Clinical Research Center Inc	Port Charlotte33952	NCT06909214	Map
FL	BayCare Health System, Inc. St Anthony's Hospital	St. Petersburg33705	NCT06298565	Map
FL	Baycare Medical Group	St. Petersburg33705	NCT06909214	Map
FL	University of South Florida	Tampa33620	NCT07284420	Map
FL	University of South Florida	Tampa33620	NCT07294170	Map
GA	Emory Brain Health Center	Atlanta30329	NCT06909214	Map
HI	Hawaii Pacific Neuroscience	Honolulu96817	NCT06909214	Map
HI	The Queen's Medical Center - West Oahu	Honolulu96813	NCT06909214	Map
IL	Ann and Robert H Lurie Children's Hospital of Chicago - Main Hospital	Chicago60611	NCT04833894	Map
IL	The University of Chicago Medicine	Chicago60637	NCT06544499	Map
IL	University of Chicago Medical Center	Chicago60615	NCT06503731	Map
IL	University of Illinois Health Outpatient Care Center	Chicago60612	NCT06655155	Map
IL	HSHS Medical Group	O'Fallon62269	NCT06909214	Map
IL	HSHS St. Elizabeth's Hospital	O'Fallon62269	NCT07217587	Map
IL	Prairie Education and Research Cooperative and HSHS Medical Group	O'Fallon62701	NCT06298565	Map
IN	Josephson Wallack Munshower Neurology, PC	Indianapolis46256	NCT07217587	Map
IA	The University of Iowa Hospitals & Clinics	Iowa City52242	NCT06544499	Map
IA	University of Iowa	Iowa City52242	NCT06298565	Map
KS	University of Kansas Medical Center	Kansas City66160	NCT06298565	Map
KY	Norton Neuroscience Institute	Louisville40241	NCT06298565	Map
LA	DelRicht Research, LLC	New Orleans70112	NCT06655155	Map
LA	Tulane University	New Orleans70112	NCT06544499	Map
MD	Johns Hopkins Asthma and Allergy Center	Baltimore21224	NCT06655155	Map
MD	Erlanger Health System	Columbia21044	NCT07294170	Map
MD	Thomas Jefferson University	Columbia21044	NCT06655155	Map
MA	Beth Israel Deaconess Medical Center	Boston02215	NCT06298565	Map
MA	Massachusetts Eye and Ear Infirmary	Boston02114	NCT06453694	Map
MA	Massachusetts General Hospital	Boston02114	NCT06298565	Map
MA	Massachusetts General Hospital	Boston02114	NCT06453694	Map
MA	UMass Memorial Medical Center	Worcester01655	NCT06909214	Map
MI	University of Michigan Hospital	Ann Arbor48109	NCT06655155	Map
MI	Henry Ford Health	Detroit48202	NCT06544499	Map
MI	Henry Ford Health System	Detroit48202	NCT06298565	Map
MI	Henry Ford Health System	Detroit48202	NCT06909214	Map
MI	Henry Ford Hospital	Detroit48202	NCT07217587	Map
MN	University of Minnesota	Minneapolis55422	NCT06544499	Map
MN	University of Minnesota	Minneapolis55455	NCT06831058	Map
NE	University of Nebraska Medical Center	Omaha68198	NCT06503731	Map
NJ	Regional Cancer Care Associates, LLC (RCCA)	Little Silver07739	NCT06544499	Map
NY	Dent Neurologic Institute - Amherst	Amherst14226	NCT07284420	Map
NY	Dent Neurologic Institute - Amherst	Amherst14226	NCT07294170	Map
NC	University of North Carolina at Chapel Hill	Chapel Hill27599	NCT04833894	Map
NC	Carolinas HealthCare System Neurosciences Institute - Neurology	Charlotte28207	NCT06392386	Map
NC	Duke University Hospital	Durham27705	NCT06503731	Map
NC	Duke University Medical Center	Durham27710	NCT06544499	Map
NC	Brody School of Medicine at East Carolina University	Greenville27834	NCT06544499	Map
NC	Velocity Clinical Research, Inc.	Raleigh27607 6010	NCT07217587	Map
NC	PPD Virtual	Wilmington28401	NCT07264426	Map
NC	Atrium Health Wake Forest Baptist	Winston-Salem27157	NCT07217587	Map
OH	Cleveland Clinic	Cleveland44195	NCT06909214	Map
OH	University Hospitals Cleveland Medical Center	Cleveland44106	NCT06544499	Map
OH	Ohio State Martha Morehouse Outpatient Care	Columbus43221-3502	NCT07284420	Map
OH	Ohio State Martha Morehouse Outpatient Care	Columbus43221-3502	NCT07294170	Map
OH	Ohio State University Hospital East	Columbus43203	NCT06544499	Map
OH	The Ohio State University Wexner Medical Center	Columbus43210	NCT06503731	Map
OK	INTEGRIS Cancer Institute of Oklahoma	Oklahoma City73109	NCT06544499	Map
OR	Oregon Health and Science University	Portland97239	NCT06298565	Map
OR	University of Colorado Hospital	Portland97239	NCT06298565	Map
PA	Perelman Center for Advanced Medicine	Philadelphia19104	NCT06655155	Map
SC	Medical University of South Carolina	Charleston29425	NCT06298565	Map
TN	Erlanger Health System	Chattanooga37403	NCT07284420	Map
TN	Erlanger Health System	Chattanooga37403-2136	NCT07294170	Map
TN	Erlanger Neuroscience Institute	Chattanooga37403	NCT06909214	Map
TX	National Neuromuscular Research Institute	Austin78759	NCT06298565	Map
TX	National Neuromuscular Research Institute	Austin78756	NCT07284420	Map
TX	National Neuromuscular Research Institute	Austin78759	NCT07294170	Map
TX	Texas Neurology	Dallas75206	NCT07217587	Map
TX	Neurology Rare Disease Center	Denton76208	NCT06392386	Map
TX	Central Texas Neurology Consultants - Elligo	Round Rock78681	NCT06909214	Map
TX	University of Texas- San Antonio - Health Science Center - PPDS	San Antonio78229	NCT07284420	Map
TX	University of Texas- San Antonio - Health Science Center - PPDS	San Antonio78229	NCT07294170	Map
VA	University of Virginia	Charlottesville22903	NCT06392386	Map
VA	University of Virginia (UVA) Health - Developmental Pediatrics Clinic	Charlottesville22903	NCT04833894	Map
VA	Virginia Commonwealth University (VCU) Medical Center Hume-Lee Transplant Center	Richmond23298	NCT06503731	Map
WA	University of Washington Medical Center	Seattle98195	NCT06503731	Map
WV	United BioSource LLC	Morgantown26508	NCT06299748	Map
WI	BCN Research, LLC - Gamma Therapeutic Center	Greenfield53228	NCT06298565	Map
WI	Center for Neurological Disorders - Greenfield	Greenfield53228-1321	NCT06909214	Map

Efgartigimod PH20 SC clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	enrolling by invitation	completed	terminated	withdrawn	not yet recruiting	unknown	available	Total
P1				4						4
P1/P2							1			1
P2	6	1		5	2	1	4			19
P2/P3	3		1	1			1			6
P3	4	4	1	7	4	1	3			24
P4	3			1			1			5
N/A	4						1	1	1	7

Recruiting Efgartigimod PH20 SC clinical trials (33)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT06298565	A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa	—	Myasthenia Gravis	680	Nov 2024
NCT06299748	A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.	—	Myasthenia Gravis	279	Nov 2023
NCT07583641	PolarisA Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults	P2	Autoimmune Encephalitis (AE)	170	Jul 2026
NCT07194850	ITPA Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)	P2/P3	Immune Thrombocytopenia (ITP)	24	Oct 2025
NCT07596849	VitaliThyA Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.	P3	Graves Disease	230	Jun 2026
NCT07570316	VitaliThyA Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease	P3	Graves' Disease	230	Jun 2026
NCT07264426	Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study	—	Chronic Inflammatory Demyelinating Polyradiculoneuropathy	200	Aug 2025
NCT05374590	ADAPT Jr +Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis	P2/P3	Generalized Myasthenia Gravis	12	Aug 2022
NCT07217587	EPICComparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis	P3	Myasthenia Gravis	115	Jan 2026
NCT05979441	ALKIVIA+A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy	P3	Myositis	240	Sep 2023
NCT06544499	advance NEXTA Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia	P3	Primary Immune Thrombocytopenia (ITP)	69	Oct 2024
NCT07025330	A Study of Efgartigimod in Patients With IgG4-Related Disease	P2	IgG4-related Disease	5	Nov 2025
NCT06831058	A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)	P2	Immune-mediated Thrombotic Thrombocytopenic Purpura	15	May 2025
NCT07294170	ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis	—	Myasthenia Gravis	70	Dec 2025
NCT07284420	ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod	P2	AChR-Ab Seropositive Generalized Myasthenia Gravis	70	Dec 2025
NCT07011589	VYVGARTTargeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)	P1/P2	Epidermolysis Bullosa (EB)	18	Jul 2026
NCT06528392	ESPSEfgartigimod for Stiff Person Syndrome (ESPS)	P2	Stiff-Person Syndrome	10	Apr 2025
NCT07231523	EFG vs IVIG in TAMG	P3	Efgartigimod	64	Dec 2025
NCT07072988	OPTIMAGEEvaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod	P4	Myasthenia Gravis, Generalized	50	Sep 2025
NCT06655155	eSScapeA Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis	P2	Systemic Sclerosis (SSc)	81	Nov 2024
NCT06503731	ShamrockA Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)	P2	Antibody-mediated Rejection	30	Aug 2024
NCT06453694	PET-AONEfgartigimod for the Treatment of Acute Optic Neuritis	P2	Optic Neuritis	20	Aug 2025
NCT06221501	Perioperative Efgartigimod for Thymoma and Myasthenia Gravis	P2	Myasthenia Gravis	30	Feb 2024
NCT06909214	ADAPT-EARLYA Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)	P4	New Onset Generalized Myasthenia Gravis (gMG)	30	Apr 2025
NCT04833894	ADAPT JrEvaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis	P2/P3	Generalized Myasthenia Gravis	12	Oct 2021
NCT06765161	Efgartigimod in IVIG Dependent Myasthenia Gravis Patients	P3	Myasthaenia Gravis	30	Feb 2025
NCT06885762	Efgartigimod for the Treatment of Guillain-Barré Syndrome	P2/P3	Guillain-Barre Syndrome (GBS)	20	Apr 2025
NCT06860633	Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod	P4	Myasthenia Gravis Crisis	20	Mar 2025
NCT06827587	Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis	N/A	Myasthenia Gravis	60	Feb 2025
NCT06392386	ADAPT Jr SCA Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis	P2/P3	Generalized Myasthenia Gravis	12	Jun 2024
NCT06497374	FACTFcRn Antagonists (Efgartigimod) for Acute NMOSD Attack	P2	Neuromyelitis Optica	63	Jul 2024
NCT06587867	Seronegative Myasthenia Gravis - Efgartigimod IV	P3	Efgartigimod	30	Jun 2023
NCT06688253	Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis	P4	Myasthenia Gravis Crisis	16	Nov 2024

Efgartigimod PH20 SC clinical trials by indication

Generalized Myasthenia Gravis (7)

NCT	Acronym	Phase	Status	Title
NCT05374590	ADAPT Jr +	P2/P3	enrolling by invitation	Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
NCT06298552	ADAPT SERON	P3	active not recruiting	A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT04833894	ADAPT Jr	P2/P3	recruiting	Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
NCT06392386	ADAPT Jr SC	P2/P3	recruiting	A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
NCT04980495	ADAPT NXT	P3	completed	An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis
NCT04818671	ADAPTSC+	P3	completed	Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis
NCT04735432	ADAPTsc	P3	completed	Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis

Myasthenia Gravis (6)

NCT	Acronym	Phase	Status	Title
NCT06298565	—	N/A	recruiting	A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
NCT06299748	—	N/A	recruiting	A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
NCT07217587	EPIC	P3	recruiting	Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
NCT07294170	—	N/A	recruiting	ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
NCT06221501	—	P2	not yet recruiting	Perioperative Efgartigimod for Thymoma and Myasthenia Gravis
NCT06827587	—	N/A	not yet recruiting	Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis

Primary Immune Thrombocytopenia (4)

NCT	Acronym	Phase	Status	Title
NCT04812925	ADVANCE SC+	P3	active not recruiting	A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
NCT04225156	ADVANCE+	P3	completed	A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
NCT04687072	ADVANCE SC	P3	completed	A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
NCT04188379	ADVANCE	P3	completed	A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (3)

NCT	Acronym	Phase	Status	Title
NCT04280718	ADHERE+	P2	active not recruiting	A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
NCT04281472	ADHERE	P2	completed	A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
NCT04777734	CIDP	N/A	available	Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Efgartigimod (2)

NCT	Acronym	Phase	Status	Title
NCT07231523	—	P3	not yet recruiting	EFG vs IVIG in TAMG
NCT06587867	—	P3	recruiting	Seronegative Myasthenia Gravis - Efgartigimod IV

Myasthenia Gravis Crisis (2)

NCT	Acronym	Phase	Status	Title
NCT06860633	—	P4	recruiting	Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod
NCT06688253	—	P4	not yet recruiting	Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis

Primary Immune Thrombocytopenia (ITP) (2)

NCT	Acronym	Phase	Status	Title
NCT06544499	advance NEXT	P3	recruiting	A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
NCT04274452	ADVANCE2	P3	withdrawn	A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)

Neuromyelitis Optica (2)

NCT	Acronym	Phase	Status	Title
NCT06497374	FACT	P2	not yet recruiting	FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack
NCT06118398	—	N/A	unknown	Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders

Thyroid Eye Disease (2)

NCT	Acronym	Phase	Status	Title
NCT06307626	UplighTED	P3	terminated	A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.
NCT06307613	UplighTED	P3	terminated	A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease

Primary Sjögren's Syndrome (2)

NCT	Acronym	Phase	Status	Title
NCT06203457	Rho plus	P2	completed	Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome
NCT05817669	rho	P2	completed	A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)

Bullous Pemphigoid (2)

NCT	Acronym	Phase	Status	Title
NCT05681481	BALLAD+	P3	terminated	A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
NCT05267600	BALLAD	P2/P3	completed	A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

Healthy Volunteers (2)

NCT	Acronym	Phase	Status	Title
NCT05163834	—	P1	completed	Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV
NCT04564066	—	P1	completed	A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers

Pemphigus Vulgaris (2)

NCT	Acronym	Phase	Status	Title
NCT04598477	ADDRESS+	P3	terminated	A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
NCT04598451	ADDRESS	P3	completed	A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

Epidermolysis Bullosa (EB) (1)

NCT	Acronym	Phase	Status	Title
NCT07011589	VYVGART	P1/P2	not yet recruiting	Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)

Autoimmune Encephalitis (AE) (1)

NCT	Acronym	Phase	Status	Title
NCT07583641	Polaris	P2	not yet recruiting	A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults

Graves Disease (1)

NCT	Acronym	Phase	Status	Title
NCT07596849	VitaliThy	P3	not yet recruiting	A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.

Graves' Disease (1)

NCT	Acronym	Phase	Status	Title
NCT07570316	VitaliThy	P3	not yet recruiting	A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

AChR-Ab Seropositive Generalized Myasthenia Gravis (1)

NCT	Acronym	Phase	Status	Title
NCT07284420	—	P2	recruiting	ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

IgG4-related Disease (1)

NCT	Acronym	Phase	Status	Title
NCT07025330	—	P2	recruiting	A Study of Efgartigimod in Patients With IgG4-Related Disease

Immune Thrombocytopenia (ITP) (1)

NCT	Acronym	Phase	Status	Title
NCT07194850	ITP	P2/P3	recruiting	A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

Myasthenia Gravis, Generalized (1)

NCT	Acronym	Phase	Status	Title
NCT07072988	OPTIMAGE	P4	recruiting	Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod

Optic Neuritis (1)

NCT	Acronym	Phase	Status	Title
NCT06453694	PET-AON	P2	recruiting	Efgartigimod for the Treatment of Acute Optic Neuritis

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (1)

NCT	Acronym	Phase	Status	Title
NCT07264426	—	N/A	recruiting	Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

Immune-mediated Thrombotic Thrombocytopenic Purpura (1)

NCT	Acronym	Phase	Status	Title
NCT06831058	—	P2	recruiting	A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

New Onset Generalized Myasthenia Gravis (gMG) (1)

NCT	Acronym	Phase	Status	Title
NCT06909214	ADAPT-EARLY	P4	recruiting	A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)

Guillain-Barre Syndrome (GBS) (1)

NCT	Acronym	Phase	Status	Title
NCT06885762	—	P2/P3	not yet recruiting	Efgartigimod for the Treatment of Guillain-Barré Syndrome

Stiff-Person Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT06528392	ESPS	P2	not yet recruiting	Efgartigimod for Stiff Person Syndrome (ESPS)

Myasthaenia Gravis (1)

NCT	Acronym	Phase	Status	Title
NCT06765161	—	P3	recruiting	Efgartigimod in IVIG Dependent Myasthenia Gravis Patients

Primary Sjogrens Disease (1)

NCT	Acronym	Phase	Status	Title
NCT06684847	Unity	P3	active not recruiting	A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

Chronic Inflammatory Demyelinating Polyneuropathy (1)

NCT	Acronym	Phase	Status	Title
NCT06637072	—	P4	completed	A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC

Systemic Sclerosis (SSc) (1)

NCT	Acronym	Phase	Status	Title
NCT06655155	eSScape	P2	recruiting	A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

Myasthenia Gravis, Ocular (1)

NCT	Acronym	Phase	Status	Title
NCT06558279	ADAPT oculus	P3	active not recruiting	A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

Guillain-Barre Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT05701189	—	P2	withdrawn	Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome

Antibody-mediated Rejection (1)

NCT	Acronym	Phase	Status	Title
NCT06503731	Shamrock	P2	recruiting	A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

Myositis (1)

NCT	Acronym	Phase	Status	Title
NCT05979441	ALKIVIA+	P3	enrolling by invitation	A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

Renal Impairment (1)

NCT	Acronym	Phase	Status	Title
NCT05927415	—	P1	completed	A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod

Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT05918978	POTS	P2	terminated	Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS

Bioequivalence (1)

NCT	Acronym	Phase	Status	Title
NCT05817435	—	P1	completed	A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults

Lupus Nephritis (1)

NCT	Acronym	Phase	Status	Title
NCT05810948	ZL-1103-013	P2	completed	A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)

Membranous Nephropathy (1)

NCT	Acronym	Phase	Status	Title
NCT05810961	ZL-1103-014	P2	terminated	A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)

Postural Orthostatic Tachycardia Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT05633407	POTS	P2	completed	Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS

Efgartigimod PH20 SC pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
OPTIMAGE	NCT07072988	P4	recruiting	Myasthenia Gravis, Generalized	50	—
ADAPT-EARLY	NCT06909214	P4	recruiting	New Onset Generalized Myasthenia Gravis (gMG)	30	—
VitaliThy	NCT07596849	P3	not yet recruiting	Graves Disease	230	—
VitaliThy	NCT07570316	P3	not yet recruiting	Graves' Disease	230	—
EPIC	NCT07217587	P3	recruiting	Myasthenia Gravis	115	—
ALKIVIA+	NCT05979441	P3	enrolling by invitation	Myositis	240	—
Unity	NCT06684847	P3	active not recruiting	Primary Sjogrens Disease	631	—
advance NEXT	NCT06544499	P3	recruiting	Primary Immune Thrombocytopenia (ITP)	69	—
ADAPT oculus	NCT06558279	P3	active not recruiting	Myasthenia Gravis, Ocular	141	—
ADAPT SERON	NCT06298552	P3	active not recruiting	Generalized Myasthenia Gravis	119	—
ADVANCE SC+	NCT04812925	P3	active not recruiting	Primary Immune Thrombocytopenia	173	—
ADVANCE+	NCT04225156	P3	completed	Primary Immune Thrombocytopenia	101	—
UplighTED	NCT06307626	P3	terminated	Thyroid Eye Disease	105	—
UplighTED	NCT06307613	P3	terminated	Thyroid Eye Disease	102	—
ADAPT NXT	NCT04980495	P3	completed	Generalized Myasthenia Gravis	69	—
BALLAD+	NCT05681481	P3	terminated	Bullous Pemphigoid	64	—
ADAPTSC+	NCT04818671	P3	completed	Generalized Myasthenia Gravis	184	—
ADDRESS+	NCT04598477	P3	terminated	Pemphigus Vulgaris	183	—
ADVANCE SC	NCT04687072	P3	completed	Primary Immune Thrombocytopenia	207	PMID 41943179
ADDRESS	NCT04598451	P3	completed	Pemphigus Vulgaris	222	—
ADVANCE	NCT04188379	P3	completed	Primary Immune Thrombocytopenia	131	PMID 37778358
ADAPTsc	NCT04735432	P3	completed	Generalized Myasthenia Gravis	110	—
ADVANCE2	NCT04274452	P3	withdrawn	Primary Immune Thrombocytopenia (ITP)	0	—
Polaris	NCT07583641	P2	not yet recruiting	Autoimmune Encephalitis (AE)	170	—
ESPS	NCT06528392	P2	not yet recruiting	Stiff-Person Syndrome	10	—
eSScape	NCT06655155	P2	recruiting	Systemic Sclerosis (SSc)	81	—
Shamrock	NCT06503731	P2	recruiting	Antibody-mediated Rejection	30	—
PET-AON	NCT06453694	P2	recruiting	Optic Neuritis	20	—
ADHERE+	NCT04280718	P2	active not recruiting	Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	229	—
FACT	NCT06497374	P2	not yet recruiting	Neuromyelitis Optica	63	—
ZL-1103-013	NCT05810948	P2	completed	Lupus Nephritis	73	—
Rho plus	NCT06203457	P2	completed	Primary Sjögren's Syndrome	24	—
POTS	NCT05918978	P2	terminated	Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome	33	—
ZL-1103-014	NCT05810961	P2	terminated	Membranous Nephropathy	8	—
POTS	NCT05633407	P2	completed	Postural Orthostatic Tachycardia Syndrome	53	PMID 39413203
rho	NCT05817669	P2	completed	Primary Sjögren's Syndrome	34	PMID 41997805
ADHERE	NCT04281472	P2	completed	Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	322	PMID 39304241

Terminated and withdrawn Efgartigimod PH20 SC trials (8)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT05701189withdrawnEvaluating Efgartigimod in Patients With Guillain-Barré Syndrome
NCT06307626terminatedA Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.
NCT06307613terminatedA Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease
NCT05681481terminatedA Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
NCT05918978terminatedOpen Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS
NCT05810961terminatedA Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)
NCT04598477terminatedA Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
NCT04274452withdrawnA Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)

All Efgartigimod PH20 SC trials (66)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT06298565		A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa	—	recruiting	680	argenx	Nov 2024
NCT06299748		A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.	—	recruiting	279	argenx	Nov 2023
NCT07583641	Polaris	A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults	P2	not yet recruiting	170	argenx	Jul 2026
NCT07194850	ITP	A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)	P2/P3	recruiting	24	argenx	Oct 2025
NCT07596849	VitaliThy	A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.	P3	not yet recruiting	230	argenx	Jun 2026
NCT07570316	VitaliThy	A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease	P3	not yet recruiting	230	argenx	Jun 2026
NCT07264426		Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study	—	recruiting	200	argenx	Aug 2025
NCT05374590	ADAPT Jr +	Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis	P2/P3	enrolling by invitation	12	argenx	Aug 2022
NCT07217587	EPIC	Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis	P3	recruiting	115	Janssen Research & Development, LLC	Jan 2026
NCT05979441	ALKIVIA+	A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy	P3	enrolling by invitation	240	argenx	Sep 2023
NCT06684847	Unity	A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome	P3	active not recruiting	631	argenx	Jan 2025
NCT06544499	advance NEXT	A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia	P3	recruiting	69	argenx	Oct 2024
NCT07025330		A Study of Efgartigimod in Patients With IgG4-Related Disease	P2	recruiting	5	Stanford University	Nov 2025
NCT06831058		A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)	P2	recruiting	15	University of Minnesota	May 2025
NCT07294170		ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis	—	recruiting	70	argenx	Dec 2025
NCT07284420		ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod	P2	recruiting	70	argenx	Dec 2025
NCT07011589	VYVGART	Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)	P1/P2	not yet recruiting	18	M. Peter Marinkovich	Jul 2026
NCT06528392	ESPS	Efgartigimod for Stiff Person Syndrome (ESPS)	P2	not yet recruiting	10	University of South Florida	Apr 2025
NCT06558279	ADAPT oculus	A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis	P3	active not recruiting	141	argenx	Sep 2024
NCT07231523		EFG vs IVIG in TAMG	P3	not yet recruiting	64	Shanghai Zhongshan Hospital	Dec 2025
NCT07072988	OPTIMAGE	Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod	P4	recruiting	50	Centre Hospitalier Universitaire de Nice	Sep 2025
NCT06655155	eSScape	A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis	P2	recruiting	81	argenx	Nov 2024
NCT06503731	Shamrock	A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)	P2	recruiting	30	argenx	Aug 2024
NCT06453694	PET-AON	Efgartigimod for the Treatment of Acute Optic Neuritis	P2	recruiting	20	Anastasia Vishnevetsky, MD, MPH	Aug 2025
NCT06298552	ADAPT SERON	A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis	P3	active not recruiting	119	argenx	Apr 2024
NCT06221501		Perioperative Efgartigimod for Thymoma and Myasthenia Gravis	P2	not yet recruiting	30	Shanghai Zhongshan Hospital	Feb 2024
NCT06909214	ADAPT-EARLY	A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)	P4	recruiting	30	argenx	Apr 2025
NCT04280718	ADHERE+	A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)	P2	active not recruiting	229	argenx	Sep 2020
NCT04833894	ADAPT Jr	Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis	P2/P3	recruiting	12	argenx	Oct 2021
NCT06765161		Efgartigimod in IVIG Dependent Myasthenia Gravis Patients	P3	recruiting	30	Clinique Neuro-Outaouais	Feb 2025
NCT06885762		Efgartigimod for the Treatment of Guillain-Barré Syndrome	P2/P3	not yet recruiting	20	Zhongming Qiu	Apr 2025
NCT06860633		Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod	P4	recruiting	20	University of Colorado, Denver	Mar 2025
NCT06827587		Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis	N/A	not yet recruiting	60	First Affiliated Hospital of Wenzhou Medical University	Feb 2025
NCT04812925	ADVANCE SC+	A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia	P3	active not recruiting	173	argenx	Nov 2021
NCT06392386	ADAPT Jr SC	A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis	P2/P3	recruiting	12	argenx	Jun 2024
NCT06497374	FACT	FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack	P2	not yet recruiting	63	Tianjin Medical University General Hospital	Jul 2024
NCT04225156	ADVANCE+	A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).	P3	completed	101	argenx	Jun 2020
NCT05701189		Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome	P2	withdrawn	0	Chafic Karam	Sep 2024
NCT06637072		A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC	P4	completed	23	argenx	Dec 2024
NCT06307626	UplighTED	A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.	P3	terminated	105	argenx	Mar 2024
NCT06307613	UplighTED	A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease	P3	terminated	102	argenx	Mar 2024
NCT04980495	ADAPT NXT	An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis	P3	completed	69	argenx	Dec 2021
NCT05810948	ZL-1103-013	A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)	P2	completed	73	argenx	Feb 2023
NCT06587867		Seronegative Myasthenia Gravis - Efgartigimod IV	P3	recruiting	30	University Health Network, Toronto	Jun 2023
NCT06118398		Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders	—	unknown	24	Feng Jinzhou	Nov 2023
NCT06688253		Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis	P4	not yet recruiting	16	Rambam Health Care Campus	Nov 2024
NCT05681481	BALLAD+	A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid	P3	terminated	64	argenx	Mar 2023
NCT06203457	Rho plus	Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome	P2	completed	24	argenx	Nov 2023
NCT04818671	ADAPTSC+	Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis	P3	completed	184	argenx	Apr 2021
NCT05267600	BALLAD	A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid	P2/P3	completed	98	argenx	Jun 2022
NCT05918978	POTS	Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS	P2	terminated	33	argenx	Jun 2023
NCT05810961	ZL-1103-014	A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)	P2	terminated	8	argenx	Feb 2023
NCT05927415		A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod	P1	completed	33	argenx	Jul 2023
NCT05633407	POTS	Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS	P2	completed	53	argenx	Sep 2022
NCT04598477	ADDRESS+	A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)	P3	terminated	183	argenx	Jul 2021
NCT05817669	rho	A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)	P2	completed	34	argenx	Apr 2023
NCT04687072	ADVANCE SC	A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia	P3	completed	207	argenx	Dec 2020
NCT04598451	ADDRESS	A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)	P3	completed	222	argenx	Dec 2020
NCT05817435		A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults	P1	completed	120	argenx	Mar 2023
NCT04281472	ADHERE	A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)	P2	completed	322	argenx	Apr 2020
NCT05163834		Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV	P1	completed	36	argenx	Nov 2021
NCT04188379	ADVANCE	A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).	P3	completed	131	argenx	Dec 2019
NCT04735432	ADAPTsc	Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis	P3	completed	110	argenx	Feb 2021
NCT04274452	ADVANCE2	A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)	P3	withdrawn	0	argenx	Jun 2020
NCT04777734	CIDP	Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	—	available	0	argenx	—
NCT04564066		A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers	P1	completed	54	argenx	Aug 2020

Efgartigimod PH20 SC clinical trials: frequently asked questions

How many Efgartigimod PH20 SC clinical trials are there?: 66 Efgartigimod PH20 SC clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 22 are actively recruiting participants. 18 are marked completed.
Are Efgartigimod PH20 SC clinical trials recruiting in 2026?: Yes — 22 Efgartigimod PH20 SC trials are actively recruiting in 2026, with 110 U.S. sites across 34 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Efgartigimod PH20 SC being studied for?: Efgartigimod PH20 SC is being studied for Generalized Myasthenia Gravis, Myasthenia Gravis, gMG, Primary Immune Thrombocytopenia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and 66 more. The trials are grouped by indication on this page.
What phase is Efgartigimod PH20 SC in?: Efgartigimod PH20 SC clinical trials span 5 Phase 4, 24 Phase 3, 19 Phase 2, 4 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Efgartigimod PH20 SC clinical trials?: The lead sponsor across the most Efgartigimod PH20 SC trials is argenx, with 17 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Efgartigimod PH20 SCas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.

Related pages on Hipa.ai:

Efgartigimod PH20 SC overview Efgartigimod PH20 SC evidence & publications